• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$5.01 $0.00 (0.00%)

Quote as of

Inspire Pharmaceuticals, Inc.

NASDAQ:ISPH

Merck Gets Warm Tender Reception In $430 Million Inspire Purchase

17 Stocks Under $5 Being Chased by Big Money Managers

Merger Arbitrage Mondays: April 11, 2011

Cramer's Mad Money - 6 Earnings and IPOs to Watch for the Coming Week (4/8/11)

Fred Hassan Isn't the Only Serial Seller in the Pharma Industry

Closing Bell: The Directionless Day (AAPL, ANF, BA, FXI, ISPH, MRK, NSM, TXN)

The Incredible Shrinking Eye Care Sector

Analyst Calls: BRCD, CREE, DUK, HRL, MOLX, RTN, SPWRA, VCLK, WTW ...

Short Ideas: 20 Small Cap Stocks With Rising Receivables

Top 16 Most Underestimated Small Cap Stocks

India Allows Use of Generic Versions of Abbott AIDS Drug: Biotech's Latest Tribulations

Inspire Pharmaceuticals: Looking for Inspiration Following Denufosol Failure

Inspire Reveals Weak Trial Results for Cystic Fibrosis Drug

Inspire's Eye Drug Hits Japan

Inspire Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Inspire Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Friday's Top Volume Gainers With Bullish Options Sentiment

Today's Strong Volume Gainers With Bullish Options Sentiment

Cramer's Mad Money - A Big Kahuna Earnings Week (10/15/10)

Inspire Pharmaceuticals to Present Finding of Cystic Fibrosis Treatment

Preparing for Inspire Pharmaceutical's 2011 Phase 3 Catalyst

Inspire Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Inspire Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

UPDATE 1-Inspire Pharma posts narrower-than-expected Q1 loss

UPDATE 1-Inspire Pharma eye drug fails in mid-stage study

HEADLINE STOCKS-U.S. small/midcap stocks to watch on March 15

UPDATE 1-Inspire Pharma posts narrower-than-expected Q4 loss

UPDATE 1-Inspire Pharma hires former Sepracor boss as CEO

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

UPDATE 1-Inspire Pharma eye drug fails in late-stage trial